Nuclera introduced an antibody triage screening service designed to speed the transition from AI or in silico hit generation to lead selection and mammalian validation. The service screens large antibody libraries using 96-plex binary cell-free expression and binding assays, narrowing candidate sets before expensive functional testing. The company launched the service following a Series C extension that supports integrating antibody expression and binding validation into workflow stages. Nuclera’s approach focuses on reducing time and cost spent on non-binders by converting early candidate pools into experimental binding data. The move targets a practical bottleneck for AI-driven antibody discovery—turning theoretical binders into experimentally confirmed candidates without dragging down project timelines.